Is Arrowhead Pharmaceuticals (ARWR) A Bargain On Strong ARO DIMER PA Trial Data?
Arrowhead Pharmaceuticals (ARWR) is back in focus after releasing interim topline data on ARO-DIMER-PA, its dual-target RNA interference drug candidate for atherosclerotic cardiovascular disease driven by mixed hyperlipidemia.
For Arrowhead Pharmaceuticals, the ARO-DIMER-PA update comes after a volatile stretch, with the share price falling 18.15% over the past week and 22.94% over the past month, even as the latest 1-year total shareholder return sits at 114.98%. This points to strong longer term gains but fading short term momentum as investors reassess risk and execution around its expanding cardiometabolic pipeline.
Scan beyond Arrowhead Pharmaceuticals to identify other cardiometabolic and biotech players that align with this type of RNA-focused momentum with our hand picked 16 high quality undiscovered gems
After a sharp pullback yet a 1 year total return above 100%, Arrowhead Pharmaceuticals now poses a harder question: Does the current valuation still compensate you for pipeline and execution risk, or has the easy upside already been taken?
Most Popular Narrative: 39% Undervalued
On the most followed view, Arrowhead Pharmaceuticals screens as undervalued, with a fair value estimate of $110.18 against the last close of $67.74. This view places substantial emphasis on its RNAi pipeline and partnership structure.
Multiple large pharma collaborations and milestone-generating partnerships (notably with Sarepta, Amgen, Takeda, and Sanofi) provide non-dilutive capital, revenue diversity, and stability independent of volatile equity markets, supporting sustained R&D investments and improving medium-term cash flow visibility.
See why 13 investors see Arrowhead Pharmaceuticals as 39% undervalued.
Result: Fair Value of $110.18 (UNDERVALUED)
Still, the Arrowhead Pharmaceuticals story can break if partner milestones slow or if higher R&D and SG&A spending outpaces the current revenue base.
Find out about the key risks to this Arrowhead Pharmaceuticals narrative.
Next Steps
Mixed sentiment around Arrowhead Pharmaceuticals is clear, with both concern and optimism in play. Consider reviewing the data promptly and forming your own judgment using our breakdown of 3 key rewards and 2 important warning signs.
Looking for more Arrowhead Pharmaceuticals style investment ideas?
If you like the risk and reward profile around Arrowhead Pharmaceuticals, do not stop here. Broaden your watchlist with other focused opportunities using the Simply Wall Street Screener.
- Target stronger price potential by hunting for quality companies that trade below their assessed value with our hand picked 29 high quality undervalued stocks.
- Prioritise resilience first and filter for businesses that pair healthier balance sheets with solid fundamentals using the curated list of solid balance sheet and fundamentals (23 results).
- Lean into stability and income by zeroing in on companies offering higher yields with our focused 6 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com